TOPLINE: A new epigenetic assay is able to stratify patients with Barrett’s esophagus into lower-risk and higher-risk categories for progression to high-grade dysplasia or esophageal adenocarcinoma within 5 years, aiding in clinical decision-making. METHODOLOGY: Researchers aimed to validate Esopredict (Previse), a polymerase chain reaction–based laboratory test that considers DNA methylation levels of four biomarkers…
